MEKhANIZM DEYSTVIYa I KLINIChESKOE PRIMENENIE METFORMINA (SIOFOR®): OBZOR LITERATURY


Cite item

Full Text

Abstract

Рассмотрены история создания и механизмы сахароснижающего действия метформина (Сиофор). Представлены данные о применении метформина с целью профилактики сахарного диабета типа 2, его влиянии на факторы риска сердечно-сосудистых заболеваний. Обсуждаются возможности использования метформина вне лечения сахарного диабета типа 2 (атеросклероз, неалкогольный жировой гепатоз, синдром поликистозных яичников). Рассматриваются побочные явления, связанные с применением метформина.

About the authors

I Yu Demidova

T V Gorokhova

References

  1. Балаболкин М.И., Креминская В.М. Эффективность и место сиофора (метформина) в терапии сахарного диабета 2 типа // Сахарный диабет. 2001. № 1. С. 1-10.
  2. Schafer G. Biguanides - a review of history, pharmacodynamics and therapy. Diab Metab (Paris) 1983;9:148-65.
  3. Misbin RI, Green I, Stadel BV, et al. Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med 1998;338:265-66.
  4. U.K. Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS ). Lancet 1998;352:837-53.
  5. Wiernsperger NF, Bailey CJ. The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms. Drugs 1999;58(Suppl.):31-39.
  6. Wu MS, Johnston P, et al. Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients. Diabetes Care 1990;13:1-8.
  7. Kozka IJ, Holman GD. Metformin blocks down-regulation of cell surface GLUT4 caused by chronic insulin treatment of rat adipocytes. Diabetes 1993;42:1159-65.
  8. Matthaei S, Reibold JP, Hamann A, et al. In vivo metformin treatment ameliorates insulin resistance: evidence for potentiation of insulin induced translocation and increased functional activity of glucose transporters in obese (fa/fa) Zucker rataadipocytes. Endocrinology 1993;133:304-11.
  9. Сuyton AC. Textbook of Medical Physiology. W.B. Saunders Co 7th Edition, 1986.
  10. Prager R, Shernthaner G, Graf H. Effect of metformin on peripheral inulin sensitivity in non insulin dependent diabetes mellitus. Diabete Metab 1986;12(6):346-50.
  11. Althoff PH, Haupt E, Pichel C. Metformin increases insulin sensitivity and first phase of the arginin - induced insulin response in type 2 diabetes. Diabetes 1991;40(Suppl. 1):342.
  12. Argaud D, Roth H, Wiemspreger N. Metformin decreases gluconeogenesis by enhancing the pyruvate kinase flux in isolated rat hepatocytes. Eur J Biochem 1993;213:1341-48.
  13. Signore A, Fiore V, Chianelli M, et al. The effect of Metformin on Liver Blood-Flow in Vivo in Normal Subjects with Non-Insulin Dependent Diabetes. Diab Res Clin Pract 1996;33(2):83-87.
  14. Zou MH, Wu Y. AMP-activated proteine kinase activation as a strategy for protecting vascular endothelial function. Clin Exp Pharmacol Physiol 2008;35:535-45.
  15. Cuthbertson J, Patterson S, Bell PM. Metformin combined with exogenous glucagons-like peptide-1 gives added benefit by improving acute glycemic control in type 2 diabetic subjects. European Association for the study of Diabetes 2008:378, abstr.
  16. Bailey CJ. Metformin - an update. Gen Pharmacol 1993;24:1299-309.
  17. DeFronzo RA, Goodman AM. The Metformin Investigator Group: Efficacy of metformin in patients with non-insulin dependent diabetes mellitus. N Engl J Med 1995;333:541-49.
  18. Tessari P, Tiengo A. Metformin treatment of rats with diet-induced overweight and hypertriglyceridemia decreases plasma triglyceride concentrations, while decreasing triglyceride and increasing ketone body output by the isolated perfused liver. Acta Diabetol 2008;21.
  19. Ohira M, Miyashita Y, Ebisuno M, et al. Effect of metformin on serum lipoprotein lipase mass levels and LDL particle size in type 2 diabetes mellitus patients. Diabetes Res Clin Pract 2007;78(1):34-41.
  20. Grant PJ. Beneficial effects of metformin on haemostasis and vascular function in man. Diabetes Metab 2003,29:6S44-52
  21. Collier A, Watson HK, Patrick AW, et al. Effect of glycaemic control, metformin and gliclazide on platelet density and aggregability in recently diagnosed type 2 (non-insulin - dependent) diabetic patients. Diabetes Metab 1989;15(6):420-25.
  22. Makimattila S, Nikkila, K, Yki-Harvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with type II diabetes mellitus. Diabetologia 1999;42:406-12.
  23. Giugliano D, Quatraro A, Consoli G, et al. Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors. Eur J Clin Pharmacol 1993;44:107-12.
  24. Morin-Papunen L, Rautio K. Metformin reduces serum C - reactive proteine levels in women with polycystic ovary syndrome. J Clin Endicrinol Metab 2003;88(10):4649-54.
  25. Schurman L, McCarthy AD, Sedlinsky C, et al. Metformin reverts deleterious effects of advanced glycation end-products (AGEs) on osteoblastic cells. Exp Clin Endocrinol Diabetes 2008;116(6):333-40.
  26. Skrha J, Kvasnicka J, Zima T Oxidative stress and endothelium influenced by metformin in type 2 diabetes mellitus. Eur J Clin Pharmacol 2007;63(12):1107-14.
  27. Meaney E, Vela A, Samaniego V. Metformin, arterial function, intima-media thickness and nitroxidation in metabolic syndrome: The Mefisto Study. J Clin Exp Pharmacol Physiol 2008;35(8):895-903.
  28. Chen SQ, Liu Q, Sun H, et al. Effects of metformin on fatty liver in insulin-resistant rats. Zhondhua Gan Zang Bing Za Zhi 2005;13(12):915-18.
  29. Lingvay I, Raskin P, Szczepaniak LS. Effect of insulin-metformin combination on hepatic steatosis in patients with type 2 diabetes. J Diabetes Complications 2007;21(3):137-42.
  30. Сreangaa AA, Bradley HM, McCormick C, et al. Use of metformin in polycystic ovary syndrome: a meta-analysis. Obstet Gynecol 2008;111(4):959-68.
  31. Salpeter S, Greyber E, Pasternak G, et al. Risk of fatal and nonfaftl lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2006;25(1):CD002967.
  32. Kamber N, Davis WA, Bruce DG, et al. Metformin and lactic acidosis in an Australian community setting: the Fremantle Diabetes Study. Med J Aust 2008;21(8):446-49.
  33. Ting RZ, Szeto CC, Chan MH, et al. Risk factors of vitamin B12 deficiency in patients receiving metformin. Arch Intern Med 2006;9(166):1975-79.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2009 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies